Like triple-negative breast cancer, HER2-positive breast cancer frequently has a high tumour mutational burden and high rate of tumour-infiltrating lymphocytes (TILs), and given this, patients have the potential to benefit from immunotherapy [90]. This evidence concerns the gene ERBB2 and neoplasm.